Bromocriptine Mesylate Improves Glucose Tolerance and Disposal in a High-Fat-Fed Canine Model.

Bromocriptine Mesylate Improves Glucose Tolerance and Disposal in a High-Fat-Fed Canine Model. Am J Physiol Endocrinol Metab. 2020 May 27;: Authors: Moore MC, Smith MS, Swift LL, Cincotta AH, Ezrokhi M, Cominos N, Zhang Y, Farmer B, Cherrington AD Abstract Bromocriptine mesylate treatment was examined in dogs fed a high fat diet (HFD) for 8 weeks. After 4 weeks on HFD, daily bromocriptine (Bromo; n=6) or vehicle (CTR; n=5) injections were administered. Oral glucose tolerance tests were performed before beginning HFD (OGTT1), 4 weeks after HFD began (Bromo only), and after 7.5 weeks on HFD (OGTT3). After 8 weeks on HFD, clamp studies were performed, with infusion of somatostatin and intraportal replacement of insulin (4xbasal) and glucagon (basal). From 0-90 min (P1), glucose was infused via peripheral vein to double the hepatic glucose load (HGL); and from 90-180 min (P2), glucose was infused via the hepatic portal vein at 4 mg·kg-1·min-1, with the HGL maintained at 2xbasal. Bromo decreased the OGTT glucose ΔAUC0-30 and ΔAUC0-120 by 62% and 27%, respectively; P<0.05 for both), without significantly altering the insulin response. Bromo dogs exhibited enhanced net hepatic glucose uptake (NHGU) compared with CTR (~33% and 21% greater, P1 and P2, respectively; P<0.05). Nonhepatic glucose uptake (nonHGU) was increased ~38% in Bromo in P2 (P<0.05). Bromo vs CTR had higher (P<0.05) rates of glucose infusion (36% and 30%) and...
Source: American Journal of Physiology. Endocrinology and Metabolism - Category: Physiology Authors: Tags: Am J Physiol Endocrinol Metab Source Type: research